Avalon GloboCare (ALBT) Competitors $5.42 +0.52 (+10.61%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$5.48 +0.06 (+1.11%) As of 02/21/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ALBT vs. MTVA, IPA, GOVX, NERV, CLRB, MYNZ, CING, TRIB, BMRA, and CRVOShould you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include MetaVia (MTVA), ImmunoPrecise Antibodies (IPA), GeoVax Labs (GOVX), Minerva Neurosciences (NERV), Cellectar Biosciences (CLRB), Mainz Biomed (MYNZ), Cingulate (CING), Trinity Biotech (TRIB), Biomerica (BMRA), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry. Avalon GloboCare vs. MetaVia ImmunoPrecise Antibodies GeoVax Labs Minerva Neurosciences Cellectar Biosciences Mainz Biomed Cingulate Trinity Biotech Biomerica CervoMed MetaVia (NASDAQ:MTVA) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, community ranking, risk, analyst recommendations, earnings, dividends and profitability. Do analysts recommend MTVA or ALBT? MetaVia presently has a consensus price target of $12.00, indicating a potential upside of 648.22%. Given MetaVia's stronger consensus rating and higher probable upside, equities research analysts clearly believe MetaVia is more favorable than Avalon GloboCare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Avalon GloboCare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation & earnings, MTVA or ALBT? MetaVia has higher earnings, but lower revenue than Avalon GloboCare. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetaViaN/AN/A-$12.47MN/AN/AAvalon GloboCare$1.31M4.53-$16.71M-$19.96-0.27 Is MTVA or ALBT more profitable? MetaVia has a net margin of 0.00% compared to Avalon GloboCare's net margin of -1,125.59%. Avalon GloboCare's return on equity of 0.00% beat MetaVia's return on equity.Company Net Margins Return on Equity Return on Assets MetaViaN/A -189.12% -122.31% Avalon GloboCare -1,125.59%N/A -73.69% Which has more risk and volatility, MTVA or ALBT? MetaVia has a beta of -0.22, meaning that its share price is 122% less volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500. Does the MarketBeat Community believe in MTVA or ALBT? MetaVia received 1 more outperform votes than Avalon GloboCare when rated by MarketBeat users. CompanyUnderperformOutperformMetaViaOutperform Votes1100.00% Underperform VotesNo VotesAvalon GloboCareN/AN/A Do institutionals and insiders believe in MTVA or ALBT? 1.4% of MetaVia shares are owned by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are owned by institutional investors. 1.1% of MetaVia shares are owned by company insiders. Comparatively, 37.3% of Avalon GloboCare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to MTVA or ALBT? In the previous week, Avalon GloboCare had 4 more articles in the media than MetaVia. MarketBeat recorded 4 mentions for Avalon GloboCare and 0 mentions for MetaVia. Avalon GloboCare's average media sentiment score of 0.54 beat MetaVia's score of 0.00 indicating that Avalon GloboCare is being referred to more favorably in the news media. Company Overall Sentiment MetaVia Neutral Avalon GloboCare Positive SummaryAvalon GloboCare beats MetaVia on 8 of the 14 factors compared between the two stocks. Get Avalon GloboCare News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALBT vs. The Competition Export to ExcelMetricAvalon GloboCareBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.93M$3.11B$5.84B$9.15BDividend YieldN/A1.55%4.75%3.85%P/E Ratio-0.2727.4925.4719.00Price / Sales4.53329.47447.5876.30Price / CashN/A168.8738.0134.83Price / Book-0.313.687.644.62Net Income-$16.71M-$71.72M$3.18B$245.85M7 Day Performance46.88%-2.50%-1.99%-2.68%1 Month Performance59.41%-0.32%-0.42%-2.19%1 Year Performance-3.64%-12.32%16.51%12.84% Avalon GloboCare Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALBTAvalon GloboCare1.0124 of 5 stars$5.42+10.6%N/A-7.4%$5.93M$1.31M-0.275News CoverageHigh Trading VolumeMTVAMetaVia1.6199 of 5 stars$1.74+0.6%$12.00+589.7%N/A$15.00MN/A0.0010Gap UpIPAImmunoPrecise Antibodies2.9766 of 5 stars$0.48-3.5%$5.00+944.7%-77.6%$14.87M$18.16M-0.6180News CoverageGOVXGeoVax Labs1.7314 of 5 stars$1.56-8.2%$14.20+810.3%-24.9%$14.73M$80,000.000.0010NERVMinerva Neurosciences3.2159 of 5 stars$2.07-6.8%$5.00+141.5%-79.3%$14.47MN/A-4.709Analyst ForecastNews CoverageCLRBCellectar Biosciences1.9774 of 5 stars$0.31+4.6%$17.67+5,533.5%-90.4%$14.45MN/A-0.1810Analyst ForecastMYNZMainz Biomed2.8692 of 5 stars$7.09-4.3%$120.00+1,592.5%-85.9%$14.18M$900,000.00-0.1130News CoverageGap UpHigh Trading VolumeCINGCingulate2.8593 of 5 stars$4.36-2.5%$16.00+267.0%+300.5%$14.00MN/A0.0020TRIBTrinity Biotech0.4003 of 5 stars$0.77-6.9%N/AN/A$13.93M$56.83M-0.34480BMRABiomerica0.4744 of 5 stars$0.75+43.9%N/A-22.6%$13.79M$5.58M-2.2160Gap UpCRVOCervoMed3.6014 of 5 stars$2.19-0.9%$42.00+1,817.8%-84.3%$13.51M$7.14M0.004Analyst UpgradeNews Coverage Related Companies and Tools Related Companies MetaVia Competitors ImmunoPrecise Antibodies Competitors GeoVax Labs Competitors Minerva Neurosciences Competitors Cellectar Biosciences Competitors Mainz Biomed Competitors Cingulate Competitors Trinity Biotech Competitors Biomerica Competitors CervoMed Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALBT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredWarning: China Launches AI Attack on AmericaIf you have any money in AI stocks, pay attention because... According to Louis Navellier, the legendary in...InvestorPlace | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalon GloboCare Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalon GloboCare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALBT Stock Alerts